Does non-Adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Pasma, Annelieke ^a   Schenk, Charlotte ^a   Timman, Reinier ^a   van't Spijker, Adriaan ^a   Appels, Cathelijne ^b   Van Der Laan, Willemijn H ^c   Van Den Bemt, Bart ^c   Goekoop, Robert ^d   Hazes, Johanna M W ^a   Busschbach, Jan J V ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c SINT MAARTENSKLINIEK   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

ADULT; ARTHRITIS; ARTICLE; COHORT ANALYSIS; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL PROCEDURES; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT REFUSAL; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; ECONOMICS; MULTIVARIATE ANALYSIS; TIME FACTOR;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS;

EID: 85011371540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171070     Document Type: Article

References (36)

1. Pasma A, van 't Spijker A, Hazes JMW, Busschbach JJV, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: A systematic review. Semin Arthritis Rheum. 2013; 43(1):18-28. doi:10.1016/j.semarthrit.2012.12.001 PMID: 23352247.
2. Van Den Bemt BJF, Zwikker HE, Van Den Ende CHM. Medication adherence in patients with rheumatoid arthritis: A critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012; 8(4):337-51. doi:10.1586/eci.12.23 PMID: 22607180.
3. Poos M, Bijenhof A, Slobbe L. Reumatoïde artritis (RA): Hoeveel zorg gebruiken patieÈnten en wat zijn de kosten?. Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid, versie 4.17 2014 23 june 2014 [cited; Available from: http://www.nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-Aandoeningen/bewegingsstelsel-en-bindweefsel/reumatoide-Artritis-ra/zorgkosten/.
4. Verstappen SMM, Verkleij H, Bijlsma JWJ, Buskens E, Kruize AA, Heurkens AHM, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis. 2004; 63(7):817-24. doi:10.1136/ard.2003.014340 PMID: 15194577.
5. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43(6):521-30. PMID: 15908846.
6. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3):492-509. doi:10.1136/annrheumdis-2013-204573 PMID: 24161836.
7. Smolen J, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010; 69(4):631-7. doi:10.1136/ard.2009.123919 PMID: 20215140.
8. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (United Kingdom). 2012; 51(SUPPL. 6):vi37-vi43.
9. Robin Dimatteo M, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes A meta-Analysis. Med Care. 2002; 40(9):794-811. doi:10.1097/01.MLR.0000024612.61915.2D PMID: 12218770.
10. Golay A. Pharmacoeconomic aspects of poor adherence: Can better adherence reduce healthcare costs? J Med Econ. 2011; 14(5):594-608. doi:10.3111/13696998.2011.597808PMID: 21732903.
11. DiMatteo MR. Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care. 2004; 42(3):200-9. PMID: 15076819.
12. DiMatteo MR. Evidence-based strategies to foster adherence and improve patient outcomes. JAAPA. 2004; 17(11):18-21. PMID: 15575518.
13. Kane S, Shaya F. Medication non-Adherence is associated with increased medical health care costs. Dig Dis Sci. 2008; 53(4):1020-4. doi:10.1007/s10620-007-9968-0 PMID: 17934828.
14. Pasma A, Van't Spijker A, Luime JJ, Walter MJM, Busschbach JJV, Hazes JMW. Facilitators and barriers to adherence in the initiation phase of disease-modifying antirheumatic drug (DMARD) use in patients with arthritis who recently started their first DMARD treatment. J Rheum. 2015; 42(3):379-85. doi:10.3899/jrheum.140693 PMID: 25512473.
15. Spinhoven P, Ormel J, Sloekers PPA, Kempen GIJM, Speckens AEM, van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997; 27:363-70. PMID: 9089829.
16. Boers M, Jacobs JWG, van Vliet Vlietland TPM, van Riel PLCM. Consensus Dutch Health Assessment Questionnaire. Ann Rheum Dis. 2007; 66:132-3. doi:10.1136/ard.2006.059451 PMID: 17178759.
17. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg: College voor zorgverzekeringen; Geactualiseerde versie 2010.
18. Tarieflijst Instellingen 2012, supplement 2. In: Zorgautoriteit N, ed. Utrecht, the Netherlands: Nederlandse Zorgautoriteit 2011.
19. Medicijnkosten. 2014 1 october 2014 [cited 2014 22 october]; Available from: http://www.medicijnkosten.nl.
20. Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits ML, Iannaccone CK, et al. Inconsistent treatment with disease-modifying antirheumatic drugs: A longitudinal data analysis. J Rheum. 2014; 41 (12):2370-8. doi:10.3899/jrheum.140306 PMID: 25320216.
21. Kroot EJJA, Van Gestel AM, Swinkels HL, Albers MMC, Van de Putte LBA, Van Riel PLCM. Chronic comorbidity in patients with early rheumatoid arthritis: A descriptive study. J Rheum. 2001; 28(7):1511-7. PMID: 11469455.
22. Osterberg L, Blaschke T. Adherence to medication. NEJM. 2005; 353(5):487-97. doi:10.1056/NEJMra050100PMID: 16079372.
23. Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014; 7:35-44. doi:10.2147/RMHP.S19801 PMID: 24591853.
24. Boulanger L, Zhao Y, Bao Y, Russell MW. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res. 2009; 9.
25. Vasiliadis HM, Dionne PA, Pre ville M, Gentil L, Berbiche D, Latimer E. The excess healthcare costs associated with depression and anxiety in elderly living in the community. Am J Geriatr Psychiatry. 2013; 21(6):536-48. doi:10.1016/j.jagp.2012.12.016 PMID: 23567409.
26. Doeglas D, Suurmeijer T, Krol B, Sanderman R, Van Leeuwen M, Van Rijswijk M. Work disability in early rheumatoid arthritis. Ann Rheum Dis. 1995; 54(6):455-60. PMID: 7632086.
27. Van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, Heurkens AHM, Haanen HCM, Bijlsma JWJ. Direct cost of rheumatoid arthritis during the first six years: A cost-of-illness study. Brit J Rheumatol. 1998; 37 (8):837-47.
28. Geuskens GA, Hazes JMW, Barendregt PJ, Burdorf A. Work and sick leave among patients with early inflammatory joint conditions. Arthritis Care Res. 2008; 59(10):1458-66.
29. Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, et al. Association of nonadherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians. Epilepsy Behav. 2008; 13(2):316-22. doi:10.1016/j.yebeh.2008.03.009 PMID: 18472303.
30. Wagner S, Lau H, Frech-Tamas F, Gupta S. Impact of medication adherence on work productivity in hypertension. Am J Pharm Benefits. 2012; 4(4):e88-e96.
31. Jacobs J, Keyserling JA, Britton M, Morgan GJ Jr, Wilkenfeld J, Christina Hutchings H. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: The medi-cal program. J Clin Epidemiol. 1988; 41(3):215-23. PMID: 3123614.
32. Sutton S, Kinmonth AL, Hardeman W, Hughes D, Boase S, Prevost AT, et al. Does Electronic Monitoring Influence Adherence to Medication? Randomized Controlled Trial of Measurement Reactivity. Ann Behav Med. 2014:1-7.
33. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-Analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333(7557):15-8. doi:10.1136/bmj.38875.675486.55PMID: 16790458.
34. Canner PL, Forman SA, Prud'homme GJ. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. NEJM. 1980; 303(18):1038-41. doi:10.1056/NEJM198010303031804 PMID: 6999345.
35. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, et al. Statin adherence and risk of accidents a cautionary tale. Circulation. 2009; 119(15):2051-7. doi:10.1161/CIRCULATIONAHA.108.824151 PMID: 19349320.
36. Haskard Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: A meta-Analysis. Med Care. 2009; 47(8):826-34. doi:10.1097/MLR.0b013e31819a5acc PMID: 19584762.